Active Biotech AB Interim report January - March 2016
April 28 2016 - 2:35AM
LUND, Sweden, April 28, 2016 (GLOBE NEWSWIRE) --
Laquinimod
- The clinical Phase 3 study CONCERTO, 0.6 mg/day, in relapsing
remitting multiple sclerosis (RRMS), with the aim to obtain market
approval in the US and Europe, is proceeding according to plan.
Study results are expected in the first half of 2017
- The clinical Phase 2 study ARPEGGIO for the treatment of
primary progressive multiple sclerosis (PPMS) is proceeding
according to plan
- The clinical Phase 2 study LEGATO-HD for the treatment of
Huntington's disease is proceeding according to plan
- Extension studies with 0.6 mg laquinimod in patients from the
Phase 3 studies ALLEGRO and BRAVO are proceeding according to
plan
- As earlier communicated the highest dose groups in the clinical
studies CONCERTO, ARPEGGIO and LEGATO-HD have been discontinued due
to cardiovascular events
Tasquinimod
- In March 2016, it was announced that the company plans to
develop tasquinimod to treat multiple myeloma and intends to seek a
collaboration partner for the project
- An expanded analysis of the secondary endpoints in the 10TASQ10
study was presented at the ASCO GU Symposium in January 2016. The
results showed that tasquinimod had positive effects on both
radiographic and PSA-based endpoints. However, as previously
communicated, overall survival (OS) was not extended, prompting the
discontinuation of all further development within prostate
cancer
ANYARA, Paquinimod (57-57) and SILC (ISI)
- Out-licensing activities are continuing
Financial summary
MSEK |
Jan. -
Mar. |
|
Full Year |
|
|
2016 |
2015 |
|
2015 |
|
|
|
|
|
|
|
Net sales |
3.9 |
2.9 |
|
16.3 |
|
|
|
|
|
|
|
Operating loss |
-16.1 |
-57.4 |
|
-177.9 |
|
|
|
|
|
|
|
Loss for the period |
-16.8 |
-58.0 |
|
-193.5 |
|
|
|
|
|
|
|
Loss per share, before and after dilution
(SEK) |
-0.19 |
-0.64 |
|
-2.15 |
|
|
|
|
|
|
|
Cash and cash equivalents (at the end of the
period) |
76.5 |
270.5 |
|
103.6 |
|
For further information, please contact:
Tomas Leanderson, President and CEO Tel: +46 (0)46 19 20 95
Hans Kolam, CFO Tel: +46 (0)46 19 20 44 Active
Biotech AB (Corp. Reg. No. 556223-9227) Box 724, SE-220 07 Lund,
Sweden Tel: +46 (0)46 19 20 00 Fax: +46 (0)46 19 11 05
The report is also available at www.activebiotech.com.
Active Biotech AB (publ) Interim report January - March 2016
http://hugin.info/1002/R/2007548/742184.pdf
HUG#2007548
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Actividentity Corp (MM) (NASDAQ:ACTI)
Historical Stock Chart
From Apr 2023 to Apr 2024